How Health Benefits Handle Experimental or Investigational Treatments

Coverage for experimental treatments sits right at the intersection of complexity, emotion, and cost. Standard employer plans (fully insured or self-funded) usually exclude anything labeled experimental, investigational, or not medically necessary. Why? Controlling costs, managing risk, and sticking to evidence-based medicine. But the line between "innovative" and "experimental" moves all the time. That means disputes, appeals, and a lot of stress for employees facing serious illness. HR administrators and plan participants need to understand the rules, the definitions, and how to appeal.

The Standard Exclusion: Definitions and Rationale

Most plan documents spell it out: no coverage for experimental or investigational procedures, drugs, or devices. How do they decide? Plans look at a few things: Is the treatment under an IRB review? Is it part of a clinical trial? Is there solid peer-reviewed evidence showing it works? Do medical specialty societies accept it as standard care? Plans also lean on recognized compendia such as the NCCN Drugs & Biologics Compendium, on FDA determinations, and on DESI designations for older drugs.

Why exclude? For plan fiduciaries under ERISA, it's their duty to spend plan money prudently, only on proven treatments. For employers, it keeps premiums from skyrocketing and avoids the risk of paying for expensive, unproven therapies. But here's the tension: when standard treatments fail, patients and their doctors will chase any option that might save a life, even if it's labeled "experimental."

Paths to Coverage for Non-Standard Treatments

Despite the exclusion, there are real paths to coverage. You just need persistence and a clear grasp of the plan's rules.

• The Formal Appeals Process: ERISA plans must offer an internal appeals process, and non-grandfathered plans must also provide independent external review. If your claim gets denied as experimental, you can appeal with new medical literature, letters from your doctors, and proof that the treatment is gaining acceptance. Deadlines run tight: urgent care appeals get a decision within 72 hours, pre-service appeals within 15 days, and post-service appeals within 30 days. The external review, done by an independent third party, is where many cases are won or lost.
• Clinical Trial Participation: The ACA bars non-grandfathered group health plans from refusing to cover routine patient costs for members in approved clinical trials for cancer or other life-threatening conditions. The plan still covers the doctor visits, lab tests, and hospital stays it would cover for any patient not in a trial. The trial sponsor usually pays for the investigational drug or device itself.
• Medical Necessity Arguments: Sometimes you can argue that for a particular patient, with no other options left, an investigational treatment is medically necessary. That shifts the conversation from "is the treatment experimental?" to "is it necessary for this person?"
• State Mandates: Many states require fully insured plans to cover routine patient costs for approved clinical trials, often cancer trials. Self-funded plans are exempt because ERISA preempts state benefit mandates. Where your plan is funded matters.

Right to Try and Expanded Access: Who Pays

Patients with life-threatening conditions can also get investigational drugs outside a trial. FDA expanded access lets a physician request an unapproved drug for a single patient when no suitable trial exists. The federal Right to Try Act, signed on May 30, 2018, opens a second route for drugs that have passed Phase 1 testing and remain under active development. Neither pathway requires an insurer to pay. The Right to Try law leaves the drug's cost, and the cost of related care, with the patient or the manufacturer. Benefits leaders who field these requests should know that access to a drug is not the same as coverage for it.

Practical Steps for Benefits Leaders

Proactive management of this issue is essential. Here's what HR and benefits leaders can do:

1. Clarity in Plan Documents: Make sure your SPD clearly defines "experimental" and "investigational" and maps out the appeals process. Ambiguity = lawsuits.
2. Educate and Empower Employees: Give employees resources on how to appeal and what clinical trial options exist. A little transparency when they're in crisis goes a long way: it builds trust and keeps things from turning adversarial.
3. Work with Your TPA and Stop-Loss Carrier: For self-funded plans, work closely with your TPA and stop-loss insurer. They have clinical teams and established protocols. Know their criteria and how they handle outside reviews.
4. Consider a Case Management Program: Set up a process that automatically flags complex cases, especially experimental treatment requests, to a nurse case manager. A coordinated, humane approach helps explore every option within the plan.
5. Benchmark and Review: Review denial patterns regularly. If you see the same issues popping up, it might be time to update your plan definitions or look at vendors that offer managed access to new therapies.

WellthCare™'s View: Prevention First

Traditional plans wrestle with the high cost and high emotion of experimental treatments at end-stage. WellthCare approaches it differently, focusing on prevention and early intervention to catch health issues before they become advanced. The model uses $0 co-pay preventive care, personalized plans, and behavioral incentives to keep people healthy within proven medicine. Better health builds automatic wealth for employees and lowers claims for the plan. The goal: reduce the need for those last-chance experimental treatment debates altogether.

Handling experimental treatment coverage is a balancing act of fiduciary duty, cost, and compassion. A clear, transparent process, paired with a focus on prevention, helps organizations support both their bottom line and their employees when they need it most.